Cidofovir
FDA-approved product (solution, intravenous), marketed as Cidofovir, Vistide.
- Registered studies
- 43
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cytomegalovirus Retinitis
- Inborn error of immunity
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Nucleosides and nucleotides excl. reverse transcriptase inhibitors
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB12
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Cidofovir, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA28.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli19.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
43registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cidofovir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367 · start 2026-03-17
Registered record
- Registry ID
- NCT07387367
- Conditions
- Adenovirus Infections
- Interventions
- cidofovir; Brincidofovir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2026-03-17
- Completion
- 2028-06-30
- Enrolment
- 180
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdenovirus InfectionsInterventioncidofovir; BrincidofovirPhasePhase 3Registry statusRecruitingA Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
NCT06439342 · start 2024-12-16
Registered record
- Registry ID
- NCT06439342
- Conditions
- Cytomegalovirus (CMV)
- Interventions
- Maribavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2024-12-16
- Completion
- 2026-12-31
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCytomegalovirus (CMV)InterventionMaribavirPhasePhase 3Registry statusRecruitingA Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
NCT06555432 · start 2024-11-14
Registered record
- Registry ID
- NCT06555432
- Conditions
- Cytomegalovirus (CMV)
- Interventions
- LIVTENCITY
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2024-11-14
- Completion
- 2028-10-01
- Enrolment
- 168
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCytomegalovirus (CMV)InterventionLIVTENCITYPhaseNot recordedRegistry statusRecruitingA Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
NCT04706923 · start 2021-08-16
Registered record
- Registry ID
- NCT04706923
- Conditions
- Adenovirus Infections; Cytomegalovirus Infection
- Interventions
- BCV
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2021-08-16
- Completion
- 2025-05-15
- Enrolment
- 53
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdenovirus Infections; Cytomegalovirus InfectionInterventionBCVPhasePhase 2Registry statusCompletedClinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males
NCT04055142 · start 2020-09-18
Registered record
- Registry ID
- NCT04055142
- Conditions
- High-grade Anal Intraepithelial Neoplasia
- Interventions
- electrocoagulation; cidofovir 1% topical ointment; sinecatechins 10% topical ointment
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2020-09-18
- Completion
- 2024-07-02
- Enrolment
- 108
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHigh-grade Anal Intraepithelial NeoplasiaInterventionelectrocoagulation; cidofovir 1% topical ointment; sinecatechins 10% topical ointmentPhasePhase 3Registry statusCompletedOpen Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
NCT03532035 · start 2018-12-15
Registered record
- Registry ID
- NCT03532035
- Conditions
- Adenovirus
- Interventions
- Brincidofovir; Standard of Care
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2018-12-15
- Completion
- 2019-05-10
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdenovirusInterventionBrincidofovir; Standard of CarePhasePhase 2Registry statusWithdrawnAirway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)
NCT03465280 · start 2018-04-01
Registered record
- Registry ID
- NCT03465280
- Conditions
- Recurrent Respiratory Papillomatosis; Human Papilloma Virus
- Interventions
- Microdebrider; Cold-steel surgery (forceps); Carbon dioxide laser; Potassium titanyl phosphate (KTP) laser; Pulsed dye laser; Radiofrequency ablation; Monopolar suction diathermy; Plasma coagulation; Other; Adjuvant therapies
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2018-04-01
- Completion
- 2022-08-31
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Respiratory Papillomatosis; Human Papilloma VirusInterventionMicrodebrider; Cold-steel surgery (forceps); Carbon dioxide laser; Potassium titanyl phosphate (KTP) laser +6 morePhaseNot recordedRegistry statusUnknownThe AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
NCT03339401 · start 2017-12-22
Registered record
- Registry ID
- NCT03339401
- Conditions
- Adenovirus
- Interventions
- Standard of Care; Brincidofovir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2017-12-22
- Completion
- 2019-05-10
- Enrolment
- 29
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdenovirusInterventionStandard of Care; BrincidofovirPhasePhase 2Registry statusTerminatedTrial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
NCT03073967 · start 2017-05-08
Registered record
- Registry ID
- NCT03073967
- Conditions
- HSV Infection
- Interventions
- Pritelivir; Investigator's choice
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-05-08
- Completion
- 2025-11-11
- Enrolment
- 158
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHSV InfectionInterventionPritelivir; Investigator's choicePhasePhase 3Registry statusCompletedEfficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
NCT02931539 · start 2016-12-22
Registered record
- Registry ID
- NCT02931539
- Conditions
- Cytomegalovirus (CMV)
- Interventions
- Maribavir; Ganciclovir; Valganciclovir; Foscarnet; Cidofovir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-12-22
- Completion
- 2020-08-17
- Enrolment
- 352
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCytomegalovirus (CMV)InterventionMaribavir; Ganciclovir; Valganciclovir; Foscarnet +1 morePhasePhase 3Registry statusCompletedIntralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.
NCT02567149 · start 2016-06
Registered record
- Registry ID
- NCT02567149
- Conditions
- Warts
- Interventions
- Cidofovir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2016-06
- Completion
- 2016-06
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWartsInterventionCidofovirPhasePhase 2Registry statusWithdrawnBevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
NCT02555800 · start 2014-12
Registered record
- Registry ID
- NCT02555800
- Conditions
- Recurrent Respiratory Papillomatosis
- Interventions
- Bevacizumab; Cidofovir; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2014-12
- Completion
- 2017-06
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Respiratory PapillomatosisInterventionBevacizumab; Cidofovir; PlaceboPhasePhase 2Registry statusUnknownIntravesical Cidofovir for Hemorrhagic Cystitis
NCT01816646 · start 2013-09
Registered record
- Registry ID
- NCT01816646
- Conditions
- Blood And Marrow Transplantation
- Interventions
- Cidofovir; Probenecid
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-09
- Completion
- 2016-12
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBlood And Marrow TransplantationInterventionCidofovir; ProbenecidPhasePhase 1Registry statusCompletedA Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients
NCT01946009 · start 2013-09
Registered record
- Registry ID
- NCT01946009
- Conditions
- HIV
- Interventions
- Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2013-09
- Completion
- 2014-09
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIVInterventionCidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.PhaseNot applicableRegistry statusCompletedA Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
NCT01769170 · start 2013-08
Registered record
- Registry ID
- NCT01769170
- Conditions
- CMV
- Interventions
- Brincidofovir; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-08
- Completion
- 2016-01
- Enrolment
- 452
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCMVInterventionBrincidofovir; PlaceboPhasePhase 3Registry statusCompleted